Paratek Pharmaceuticals, Inc.
PRTK
PRTK was delisted on the 20th of September, 2023.
0 hedge funds and large institutions have $0 invested in Paratek Pharmaceuticals, Inc. in 2023 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 66 closing their positions.
100% less funds holding
Funds holding: 66 → 0 (-66)
100% less capital invested
Capital invested by funds: $47M → $0 (-$47M)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 66
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $1K
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NAM
Nexpoint Asset Management
Dallas,
Texas
|
-$5.52M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$4.92M |
| 3 |
GAI
General American Investors
New York
|
-$4.07M |
| 4 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
-$3.83M |
| 5 |
BC
Bruce & Co
Chicago,
Illinois
|
-$3.44M |
PRTK Hedge Fund Activity: Q3 2023 in Review
0 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Paratek Pharmaceuticals, Inc. (PRTK) for Q3 2023, worth a combined $0 — down 100% from $47M a quarter earlier.
Sellers outnumbered buyers: 66 funds closed out of PRTK and 0 opened new positions — a net loss of 66 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Nexpoint Asset Management, exiting entirely with an estimated $5.52M sold.
- 0 institutional investors held Paratek Pharmaceuticals, Inc. (PRTK) as of Q3 2023, down from 66 in Q2 2023.
- Funds reported $0 of Paratek Pharmaceuticals, Inc. stock for Q3 2023, down 100% quarter-over-quarter.
- 0 funds opened new Paratek Pharmaceuticals, Inc. positions in Q3 2023 and 66 closed out, a net change of -66 holders.
- The largest Paratek Pharmaceuticals, Inc. seller in Q3 2023 was Nexpoint Asset Management, an estimated $5.52M sold.
Based on aggregated 13F filings for Q3 2023.